MedPath

Hydrochlorothiazide

Generic Name
Hydrochlorothiazide
Brand Names
Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
Drug Type
Small Molecule
Chemical Formula
C7H8ClN3O4S2
CAS Number
58-93-5
Unique Ingredient Identifier
0J48LPH2TH
Background

Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.

Hydrochlorothiazide was granted FDA approval on 12 February 1959.

Indication

Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.

Associated Conditions
Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke

Use of Nanotechnology Structured Water for the Prevention of Recurrent Stone Formation

Not Applicable
Completed
Conditions
Renal Stones
Idiopathic Hypercalciuria
Interventions
Dietary Supplement: structured nano-water
Other: ordinary bottled drinking water
First Posted Date
2024-11-08
Last Posted Date
2024-11-08
Lead Sponsor
ALI KAMAL M. SAMI
Target Recruit Count
325
Registration Number
NCT06681116
Locations
🇮🇶

College of Medicine, University of Suliamani, Sulaymaniyah, Kurdistan Region, Iraq

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention

Phase 2
Recruiting
Conditions
Kidney Stone
Interventions
First Posted Date
2023-11-01
Last Posted Date
2025-02-19
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
99
Registration Number
NCT06111885
Locations
🇨🇭

Inselspital, Department of Nephrology and Hypertension, Bern, Switzerland

Multi-Omics to Predict the Blood Pressure Response to Antihypertensives

Phase 4
Recruiting
Conditions
Primary Hypertension
Interventions
First Posted Date
2023-06-23
Last Posted Date
2024-06-10
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
96
Registration Number
NCT05917275
Locations
🇳🇱

Radboudumc, Nijmegen, Netherlands

Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

Phase 4
Not yet recruiting
Conditions
Urolithiasis
Hyperoxaluria
Interventions
First Posted Date
2022-07-05
Last Posted Date
2023-10-23
Lead Sponsor
Medical University of Vienna
Target Recruit Count
32
Registration Number
NCT05443932
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

Phase 3
Not yet recruiting
Conditions
ADPKD
Interventions
First Posted Date
2022-05-13
Last Posted Date
2023-09-29
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
300
Registration Number
NCT05373264
Locations
🇩🇪

Charité University Hospital, Berlin, Germany

🇬🇧

Addenbrooke's Hospital, Cambridge, United Kingdom

🇧🇪

Cliniques Universitaires Saint-Luc, Brussel, Belgium

and more 10 locations

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide

Active, not recruiting
Conditions
Hypertension
Interventions
Drug: Dihydropyridine calcium channel blocker
First Posted Date
2021-11-18
Last Posted Date
2023-07-18
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
163720
Registration Number
NCT05125224
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Mitigating the Pro-inflammatory Phenotype of Obesity

Phase 1
Recruiting
Conditions
Blood Pressure
Insulin Resistance
Diabetes
Diuretics Drug Reactions
Sympathetic Nerve Activity
Obesity
Interventions
First Posted Date
2021-06-22
Last Posted Date
2024-10-08
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
60
Registration Number
NCT04934228
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction

Early Phase 1
Active, not recruiting
Conditions
Chronic Pain
Diuretics Drug Reactions
Hypertension
SCS
Interventions
First Posted Date
2020-12-21
Last Posted Date
2024-10-08
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
36
Registration Number
NCT04676399
Locations
🇺🇸

The Marc A. Asher Comprehensive Spine Center at the Kansas University Medical Center, Kansas City, Kansas, United States

Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study)

Phase 1
Completed
Conditions
Photosensitivity
Interventions
First Posted Date
2020-12-04
Last Posted Date
2021-11-19
Lead Sponsor
Universität des Saarlandes
Target Recruit Count
30
Registration Number
NCT04654312
Locations
🇩🇪

Saarland University Hospital, Homburg, Saarland, Germany

Sympathetic Regulation of Large Artery Stiffness in Humans With ISH

Early Phase 1
Recruiting
Conditions
Stiffness, Aortic
Hypertension, Systolic
Interventions
First Posted Date
2020-06-09
Last Posted Date
2024-04-19
Lead Sponsor
University of Iowa
Target Recruit Count
78
Registration Number
NCT04423627
Locations
🇺🇸

Amy Stroud, Iowa City, Iowa, United States

🇺🇸

University of Iowa, Iowa City, Iowa, United States

© Copyright 2025. All Rights Reserved by MedPath